Prophylaxis in real life scenarios
- PMID: 24762285
- DOI: 10.1111/hae.12425
Prophylaxis in real life scenarios
Abstract
Prophylaxis has become the standard mantra of care for those individuals with severe haemophilia A and B. Primary prophylaxis is advocated to prevent the occurrence of symptomatic acute spontaneous haemarthroses and to preserve joint structure and function. Typically, twice or thrice weekly infusions of factor VIII or IX concentrates are integral to this treatment approach. Secondary prophylaxis is initiated after the relentless cycle of progressive joint damage has been triggered by prior haemarthroses and is intended to preserve existing joint health by preventing additional spontaneous bleeding events. Event-driven prophylaxis involves the administration of clotting factor concentrates to prevent acute traumatic bleeds, which are anticipated to occur in association with surgical or physical trauma. This regimen enhances the effectiveness of primary or secondary prophylaxis protocols or on-demand approaches to replacement therapy. Besides the marked reduction in the so-called annual bleed rate, prophylaxis regimens frequently increase personal self-confidence to embark on a more active and physical lifestyle; however, in reality, prophylaxis must be individualized in accordance with bleeding phenotypes, with the unique pharmacokinetic profile of administered replacement clotting factor concentrates, with the specific clinical scenario, and with the degree of intensity anticipated for any physical activity. The introduction of extended half-life replacement products will also influence how these prophylaxis regimens will be accomplished. The following scenarios will discuss how prophylaxis regimens can be implemented to protect the individual from developing spontaneous and activity-induced acute bleeding complications and to maintain an improved quality of life.
Keywords: bleed; bypassing agent; dose; haemarthrosis; prophylaxis; sports.
© 2014 John Wiley & Sons Ltd.
Similar articles
-
A comparison of traditional vs. Canadian tailored prophylaxis dosing of prophylactic factor infusions in children with haemophilia A and B in a single hemophilia treatment center.Haemophilia. 2012 Jul;18(4):561-7. doi: 10.1111/j.1365-2516.2011.02741.x. Epub 2012 Jan 5. Haemophilia. 2012. PMID: 22221939
-
Role of enhanced half-life factor VIII and IX in the treatment of haemophilia.Br J Haematol. 2015 Jun;169(6):768-76. doi: 10.1111/bjh.13360. Epub 2015 Mar 7. Br J Haematol. 2015. PMID: 25754016 Review.
-
Changing paradigm of prophylaxis with longer acting factor concentrates.Haemophilia. 2014 May;20 Suppl 4:99-105. doi: 10.1111/hae.12405. Haemophilia. 2014. PMID: 24762284 Review.
-
The use of prophylaxis in 2663 children and adults with haemophilia: results of the 2006 Canadian national haemophilia prophylaxis survey.Haemophilia. 2008 Sep;14(5):923-30. doi: 10.1111/j.1365-2516.2008.01810.x. Epub 2008 Jul 14. Haemophilia. 2008. PMID: 18637844
-
Prophylaxis for severe haemophilia: clinical challenges in the absence as well as in the presence of inhibitors.Haemophilia. 2008 Jul;14 Suppl 3:196-201. doi: 10.1111/j.1365-2516.2008.01736.x. Haemophilia. 2008. PMID: 18510542
Cited by
-
Personalized Prophylaxis with myPKFiTCE: A Real-World Cost-Effectiveness Analysis in Haemophilia A Patients.Medicina (Kaunas). 2023 Dec 24;60(1):34. doi: 10.3390/medicina60010034. Medicina (Kaunas). 2023. PMID: 38256294 Free PMC article.
-
Association of physical activity with bleeding events and safety in patients with haemophilia A starting emicizumab prophylaxis: an interim analysis of the TSUBASA study.Int J Hematol. 2024 Jan;119(1):14-23. doi: 10.1007/s12185-023-03679-8. Epub 2023 Dec 15. Int J Hematol. 2024. PMID: 38100026 Free PMC article.
-
The frequency of complications in a cohort of patients diagnosed with hemophilia A and hemophilia B receiving prophylactic treatment in Colombia: A retrospective noninterventional study.PLoS One. 2023 Nov 27;18(11):e0286187. doi: 10.1371/journal.pone.0286187. eCollection 2023. PLoS One. 2023. PMID: 38011251 Free PMC article.
-
Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Real Life: One-Year Clinical and Economic Outcomes.Drugs Real World Outcomes. 2021 Dec;8(4):527-535. doi: 10.1007/s40801-021-00259-2. Epub 2021 Jun 25. Drugs Real World Outcomes. 2021. PMID: 34170499 Free PMC article.
-
The potential correlation between patient-reported symptoms and the use of additional haemostatic medication for joint bleeding in haemophilia patients with inhibitors: a post hoc exploratory analysis of recombinant activated factor VII data from the ADEPT2 trial.Blood Coagul Fibrinolysis. 2017 Apr;28(3):224-229. doi: 10.1097/MBC.0000000000000584. Blood Coagul Fibrinolysis. 2017. PMID: 27427786 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical